ALKS · Insider Trading
Alkermes Inc. plc
Every open-market purchase and sale reported by ALKS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
13
code S
Reporting Insiders
16
current holders
ALKS — Recent Form 4 Transactions (latest 2026-11-03)
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-03 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,035 | −$93.96K |
| 2026-10-09 | Joshua Reed | SVP, Chief Financial Officer | MIXED | +5,095 | −$163.21K |
| 2026-10-09 | Anne Clem Whitaker | Director | A | +25,237 deriv. | — |
| 2026-10-02 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,034 | −$83.46K |
| 2026-09-03 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,034 | −$97.65K |
| 2026-09-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | −4,000 | −$299.92K |
| 2026-08-17 | Christian Todd Nichols | SVP, Chief Commercial Officer | Sell | −7,576 | −$372.94K |
| 2026-08-07 | Blair Curtis Jackson | President & CEO, Alkermes plc | A | +217,534 deriv. | — |
| 2026-08-03 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,034 | −$98.81K |
| 2026-08-03 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | −4,000 | −$314.82K |
| 2026-08-03 | nancy lynn MD snyderman | Director | MIXED | — | −$161.34K |
| 2026-07-06 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,034 | −$109.90K |
| 2026-07-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | −4,000 | −$366.92K |
| 2026-06-12 | Christopher I Wright | Director | Sell | −2,000 | −$90.20K |
| 2026-06-04 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,034 | −$87.56K |
| 2026-06-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | −4,000 | −$278.34K |
| 2026-05-29 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | — | −$371.03K |
| 2026-05-22 | Shane Cooke | Director | A | +16,947 deriv. | — |
| 2026-05-22 | Shane Cooke | Director | MIXED | +2,935 | −$118.50K |
| 2026-05-22 | Frank Anders Wilson | Director | MIXED | +4,667 | −$54.50K |
| 2026-05-22 | Brian P McKeon | Director | MIXED | +4,667 | −$54.50K |
| 2026-05-22 | nancy lynn MD snyderman | Director | MIXED | +4,667 | −$54.50K |
| 2026-05-22 | Richard Gaynor | Director | A | +16,947 deriv. | — |
| 2026-05-22 | Richard Gaynor | Director | MIXED | +4,667 | −$54.50K |
| 2026-05-22 | Nancy Lurker | Director | MIXED | +4,667 | −$54.50K |
| 2026-05-22 | Cato T Laurencin | Director | MIXED | +4,667 | −$54.50K |
| 2026-05-22 | Christopher I Wright | Director | MIXED | +4,667 | −$54.50K |
| 2026-05-04 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,034 | −$67.53K |
| 2026-05-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | −4,000 | −$203.86K |
| 2026-04-13 | Nancy Lurker | Director | MIXED | +2,850 | −$30.06K |
| 2026-04-06 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −2,034 | −$70.32K |
| 2026-04-01 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | −4,000 | −$222.90K |
| 2026-03-04 | Richard F Pops | Director and CEO, Alkermes plc | A | +88,843 deriv. | — |
| 2026-03-04 | Blair Curtis Jackson | EVP, Chief Operating Officer | A | +138,978 deriv. | — |
| 2026-03-04 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | Sell | −6,890 | −$201.81K |
| 2026-03-04 | Christian Todd Nichols | SVP, Chief Commercial Officer | Sell | −6,000 | −$180.00K |
| 2026-03-04 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | −4,000 | −$170.79K |
| 2026-03-04 | Joshua Reed | SVP, Chief Financial Officer | A | +97,284 deriv. | — |
| 2026-03-04 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | Sell | −4,068 | −$120.11K |
| 2026-02-27 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | +3,817 | −$93.70K |
| 2026-02-27 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | MIXED | +3,817 | −$93.70K |
| 2026-02-27 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | +1,939 | −$24.83K |
| 2026-02-27 | Blair Curtis Jackson | EVP, Chief Operating Officer | MIXED | +4,627 | −$113.55K |
| 2026-02-27 | Christian Todd Nichols | SVP, Chief Commercial Officer | MIXED | +3,007 | −$73.84K |
| 2026-02-25 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | +1,611 | −$21.63K |
| 2026-02-25 | Christian Todd Nichols | SVP, Chief Commercial Officer | MIXED | +3,562 | −$91.58K |
| 2026-02-25 | Blair Curtis Jackson | EVP, Chief Operating Officer | MIXED | +4,858 | −$124.90K |
| 2026-02-25 | Craig C. Hopkinson | EVP R&D, Chief Medical Officer | MIXED | +4,275 | −$109.90K |
| 2026-02-25 | David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | MIXED | +4,275 | −$109.90K |
| 2026-02-20 | Samuel Joseph Parisi | VP, Finance (Interim PAO) | MIXED | +3,340 | −$53.93K |
ALKS — Current Insider Holders
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Richard F Pops | Director and CEO, Alkermes plc | 1,377,740 | $62.74M |
| Blair Curtis Jackson | President & CEO, Alkermes plc | 245,003 | $11.16M |
| David Joseph Gaffin | EVP, CLO, Alkermes, Inc. | 219,353 | $9.99M |
| Iain Michael Brown | SVP, Chief Financial Officer | 150,690 | $6.86M |
| Shane Cooke | Director | 106,679 | $4.86M |
| Christian Todd Nichols | SVP, Chief Commercial Officer | 102,193 | $4.65M |
| Craig C. Hopkinson | EVP R&D, Chief Medical Officer | 74,389 | $3.39M |
| Brian P McKeon | Director | 48,536 | $2.21M |
| Richard Gaynor | Director | 37,226 | $1.70M |
| nancy lynn MD snyderman | Director | 36,178 | $1.65M |
| Frank Anders Wilson | Director | 35,751 | $1.63M |
| Cato T Laurencin | Director | 33,769 | $1.54M |
| Christopher I Wright | Director | 25,680 | $1.17M |
| Samuel Joseph Parisi | VP, Finance (Interim PAO) | 23,934 | $1.09M |
| Nancy Lurker | Director | 18,222 | $829.74K |
| Joshua Reed | SVP, Chief Financial Officer | 5,095 | $232.00K |
ALKS Insider Trading FAQ
Who are the insiders at ALKS?
16 officers, directors and 10%+ beneficial owners currently report holdings in ALKS via SEC Form 4.
Are ALKS insiders buying or selling?
Across the 50 most recent Form 4 filings for ALKS, 0 were open-market purchases (code P) and 13 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is ALKS insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent ALKS filing is dated 2026-11-03.
How to read Form 4 activity
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALKS quote page; the site-wide leaderboard is on the insider transactions hub.
More on ALKS
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.